Imunon (IMNN) Stock News

IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy, has announced a 1-for-15 reverse stock split effective July 25, 2025. The company's outstanding shares will be reduced from 31.8 million to approximately 2.1 million.

The reverse split aims to ensure IMUNON meets Nasdaq Capital Market's minimum bid price requirement for continued listing. The stock will continue trading under the symbol "IMNN" but with a new CUSIP number (15117N701). Stockholders approved the split at the July 11 Annual Meeting, authorizing a ratio range of 1-for-5 to 1-for-18.

IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has received an extension from the Nasdaq Hearing Panel to maintain its stock market listing.

The Panel has granted IMUNON's request for an exception after reviewing the company's compliance strategies. The company has already achieved compliance with the Equity Rule through recent fundraising activities and must now focus on meeting the minimum shareholder equity requirement and minimum bid price requirement within the approved timeframe.

CEO Stacy Lindborg expressed confidence in executing the compliance plan to maintain Nasdaq listing and deliver long-term shareholder value.

IMUNON (NASDAQ: IMNN), a clinical-stage biotechnology company, has submitted a compliance plan to Nasdaq to address listing requirements concerns. The company is working to meet minimum bid price and stockholders' equity requirements for continued listing on The Nasdaq Capital Market.

The company has requested a hearing before The Nasdaq Hearings Panel and expects to receive an additional 180-day compliance period. Trading of IMNN stock will continue during the hearing process. As of May 31, 2025, IMUNON's stockholders' equity exceeds $3.0 million, meeting Nasdaq's listing threshold.

IMUNON is currently advancing its lead program, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer treatment, which is in Phase 3 development. The company has initiated the Phase 3 (OVATION 3) trial in the U.S. and Canada following successful Phase 2 (OVATION 2) trial results.

IMUNON presented positive Phase 2 translational data for IMNN-001, its DNA-mediated immunotherapy for advanced ovarian cancer, at ESMO Gynaecological Cancers Congress 2025. The OVATION 2 Study involving 112 participants showed that IMNN-001 (100 mg/m2) administered with standard chemotherapy induced significant increases in key anti-cancer immune cytokines: IL-12 (27-fold), IFN-γ (62-fold), and TNF-α (36-fold) in the peritoneal cavity. These results complement previously reported overall survival data at ASCO 2025, where IMNN-001 demonstrated meaningful improvements in overall survival, progression-free survival, and surgical response with a favorable safety profile. The company has initiated its pivotal Phase 3 OVATION 3 Study with two trial sites launched in May 2025.

IMUNON announced that its PlaCCine DNA vaccine technology abstract was selected for oral presentation at the 10th International Conference on Vaccines Research & Development. The Phase 1 trial results of IMNN-101, targeting COVID-19's Omicron XBB1.5 variant, showed promising outcomes with a single dose. Key findings include 6-month durability data demonstrating up to 3-fold median increase in neutralizing antibody titers, with stronger responses in higher dose cohorts (2.0mg and 1.0mg). The vaccine proved safe with no serious adverse effects. PlaCCine technology offers advantages over mRNA vaccines, including better durability, temperature stability, and easier manufacturing. IMUNON is actively seeking strategic partners to advance this technology.

IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, announced that CEO Dr. Stacy Lindborg will present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12, 2025, at 11:30 a.m. ET. The presentation will be an interactive online event allowing real-time investor questions. Investors can pre-register for the virtual presentation through the Virtual Investor Conferences site. Those unable to attend live can access an archived webcast later through IMUNON's website under the News & Investors section.

IMUNON (NASDAQ: IMNN) announced positive Phase 2 OVATION 2 Study results for IMNN-001 in treating newly diagnosed advanced ovarian cancer. The study showed significant improvements across multiple endpoints, with a median 13-month increase in overall survival (46 vs. 33 months) and a 3-month increase in progression-free survival (14.9 vs. 11.9 months) compared to standard care. The trial demonstrated enhanced efficacy when combined with PARP inhibitors, with median overall survival not reached after 5+ years versus 37 months for standard care. The drug showed particular promise in both HRP and HRD+ patients, including those with BRCA mutations. IMNN-001 doubled the complete/near-complete histopathological response rate (26.1% vs. 13.0%) and improved surgical outcomes with no macroscopic residual tumor (64.6% vs. 52.1%). The treatment maintained a favorable safety profile with no serious immune-related adverse events.

IMUNON (NASDAQ: IMNN) announced significant progress in their Phase 2 OVATION 2 Study for IMNN-001, their lead candidate for advanced ovarian cancer treatment. The study demonstrated remarkable results, showing a 13-month extension in median overall survival (46 vs. 33 months) compared to standard care. For patients receiving PARP inhibitors, median survival in the IMNN-001 arm exceeded 5 years. The drug showed enhanced efficacy in HRD+ and BRCA populations with a hazard ratio of 0.42, and maintained a favorable safety profile with manageable side effects. The company is now advancing to Phase 3 OVATION 3 Study with FDA support. IMNN-001, powered by the TheraPlas platform, represents a potential breakthrough as the first immunotherapy showing survival benefits in frontline ovarian cancer treatment with minimal side effects.

IMUNON (NASDAQ: IMNN) has closed a private placement offering priced at-the-market under Nasdaq rules, securing $3.25 million in initial gross proceeds through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which if fully exercised, could generate up to $6.5 million in additional gross proceeds.

The warrants will be exercisable at $0.45 per share following stockholder approval and will expire three years from that date. H.C. Wainwright & Co. served as the exclusive lead placement agent, with Brookline Capital Markets as co-placement agent. The company plans to use the proceeds for working capital and general corporate purposes.